Source:http://linkedlifedata.com/resource/pubmed/id/19208420
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2009-3-31
|
| pubmed:abstractText |
Cytotoxic agents like Hydroxyurea, Busulfan and Interferon-alpha are to date the most commonly used therapeutic approaches in Essential Thrombocythemia (ET). However, few data on the efficacy and safety of these agents in the long-term are currently available. We report a retrospective analysis of the long-term outcome of 386 consecutive ET patients, followed at single Institution for a median follow-up of 9.5 years (range, 3-28.5). Cytoreductive therapy was administered to 338 patients (88%), obtaining a response in 86% of cases. Forty-five patients (12%) experienced a thrombosis. Among baseline characteristics, only history of vascular events prior to ET diagnosis predicted a higher incidence of thrombosis. Evolution in acute leukemia/myelofibrosis occurred in 6 (1,5%) and 20 (5%) patients, and was significantly higher in patients receiving sequential cytotoxic agents. Overall survival was 38% at 19 years and was poorer for patients older than 60 years, with higher leukocytes count (>15 x 10(9)/L), hypertension and mellitus diabetes at ET diagnosis and for patients experiencing a thrombotic event during follow-up. Cytoreductive therapy was effective in decreasing platelet number with negligible toxicity; however, thrombocytosis control did not reduce the incidence of thrombosis and, for patients who received sequential therapies, the probability of disease evolution was higher and survival was poorer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1096-8652
|
| pubmed:author |
pubmed-author:BaccaraniMicheleM,
pubmed-author:CataniLuciaL,
pubmed-author:De VivoAntonioA,
pubmed-author:FiacchiniMauroM,
pubmed-author:LucchesiAlessandroA,
pubmed-author:OttavianiEmanuelaE,
pubmed-author:PalandriFrancescaF,
pubmed-author:PolverelliNicolaN,
pubmed-author:SalmiFedericaF,
pubmed-author:TestoniNicolettaN,
pubmed-author:VianelliNicolaN
|
| pubmed:copyrightInfo |
Copyright 2008 Wiley-Liss, Inc.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
84
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
215-20
|
| pubmed:meshHeading |
pubmed-meshheading:19208420-Adult,
pubmed-meshheading:19208420-Aged,
pubmed-meshheading:19208420-Aged, 80 and over,
pubmed-meshheading:19208420-Comorbidity,
pubmed-meshheading:19208420-Cytostatic Agents,
pubmed-meshheading:19208420-Diabetes Mellitus,
pubmed-meshheading:19208420-Disease Progression,
pubmed-meshheading:19208420-Drug Therapy, Combination,
pubmed-meshheading:19208420-Female,
pubmed-meshheading:19208420-Follow-Up Studies,
pubmed-meshheading:19208420-Hemorrhage,
pubmed-meshheading:19208420-Humans,
pubmed-meshheading:19208420-Hypertension,
pubmed-meshheading:19208420-Incidence,
pubmed-meshheading:19208420-Male,
pubmed-meshheading:19208420-Middle Aged,
pubmed-meshheading:19208420-Neoplasms, Second Primary,
pubmed-meshheading:19208420-Platelet Aggregation Inhibitors,
pubmed-meshheading:19208420-Retrospective Studies,
pubmed-meshheading:19208420-Survival Analysis,
pubmed-meshheading:19208420-Thrombocythemia, Essential,
pubmed-meshheading:19208420-Thrombophilia,
pubmed-meshheading:19208420-Thrombosis
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
|
| pubmed:affiliation |
Department of Hematology and Medical Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|